292 research outputs found
Normales Knochenmark und häufige reaktive Veränderungen
Zusammenfassung: Die histologische Knochenmarkuntersuchung spielt, wegen ihrer großen Aussagekraft bei relativ geringem Aufwand eine bedeutende Rolle in der Diagnostik von hämatologischen und nichthämatologischen Erkrankungen. Dafür ist die Kenntnis des normalen Knochenmarks mit seiner individuellen, insbesondere altersabhängigen, Variabilität, unentbehrlich. Neben entnahmebedingten Artefakten, die falsch interpretiert werden können, oder suboptimal fixierten bzw. verarbeiteten Biopsien, die diagnostisch überbewertet werden, gibt es eine Vielfalt von reaktiven Knochenmarkveränderungen, die einen neoplastischen Prozess vortäuschen und zu schwerwiegenden diagnostischen Fehlern führen können. Bei derartigen nichtneoplastischen Veränderungen können ein oder auch mehrere Kompartimente der Hämatopoiese qualitativ und quantitativ betroffen sein. Es kann zu Verteilungs- bzw. Architekturstörungen und/oder zu Veränderungen des Knochenmarkstromas kommen. Eine optimale Knochenmarkdiagnostik erfordert, neben Spezialfärbungen, zusätzlich oftmals immunhistochemische Untersuchungen und manchmal molekularpathologische Analysen. Mehr als bei anderen Organbiopsien ist die Kenntnis klinischer Befunde, insbesondere vorangegangener Therapien, relevant, um eine korrekte Diagnose zu stellen. In diesem Beitrag sind neben dem normalen Knochenmark die häufigsten reaktiven Veränderungen dargestell
Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3.
Systemic mastocytoses represent neoplastic proliferations
of mast cells. In about 20% of cases systemic
mastocytoses are accompanied by clonal haematopoietic
non-mast cell-lineage disorders, most commonly myeloid
neoplasms. A case of systemic mastocytosis carrying the
characteristic mutation at codon 816 (D816V) in the KIT
gene of mast cells, with two concurrent accompanying
clonal haematopoietic non-mast cell-lineage disorders,
chronic myeloproliferative disease, unclassifiable and
precursor B lymphoblastic leukaemia is documented. Both
accompanying clonal haematopoietic non-mast cell-lineage
disorders carried the wild-type KIT gene, but had a
novel t(13;13)(q12;q22) involving the FLT3 locus at
13q12. The chronic myeloproliferative disease, unclassifiable
and the precursor B lymphoblastic leukaemia were
cured by syngenous stem cell transplantation, but the
systemic mastocytosis persisted for more than 10 years.
The additional impact of molecular techniques on the
correct diagnosis in haematological malignancies is
highlighted, and evidence is provided that, apart from
internal tandem duplications and mutations, FLT3 can be
activated by translocations
Klonale Verwandtschaft von Hodgkin-Lymphomen und deren Rezidiven
Zusammenfassung: In dieser Studie untersuchten wir, ob es sich bei Rezidiven von klassischen Hodgkin-Lymphomen (HL) um Rezidive im engeren Sinn oder aber um klonal unverwandte Sekundärtumoren handelt. Die Untersuchungen erfolgten an formalinfixierten, paraffineingebetteten Gewebeproben von 11Patienten. Hodgkin- bzw. Sternberg-Reed-Riesenzellen wurden nach immunhistochemischer Markierung mit CD30 mittels Laser mikrodisseziert und die Fragmentlängen des Schwerkettenimmunglobulin-Gens (IgH) unter Verwendung von FR3- und J-Konsensusprimern analysiert. Zwei Frührezidive nach einer HL-Erstdiagnose zeigten klonale Verwandschaft zu den Primärtumoren, während 3 von 4Frührezidiven nach einem Erst- oder Zweitrezidiv nicht mit dem vorangegangenen HL verwandt waren. Drei Spätrezidive waren mit dem ursprünglichen HL klonal unverwandt. Wir schließen daraus, dass es sich bei so genannten "Rezidiven" von HL z.T. um klonal unverwandte Zweitneoplasien handeln kann, was möglicherweise von therapeutischer Relevanz sein könnt
Functionalized mesoporous silica nanoparticles for oral delivery of budesonide
Non-functionalized and amino-functionalized mesoporous silica nanoparticle were loaded with anti-inflammatory drug budesonide and additionally post-coated with bioadhesive polymer (carbopol). TEM images showed spherical shape of the nanoparticles and slightly higher polydispersity after coating with carbopol. Nitrogen physisorption and thermogravimetic analysis revealed that more efficient loading and incorporation into the pores of nanoparticles was achieved with the amino-functionalized silica carrier. Infrared spectra indicated that the post-coating of these nanoparticles with carbopol led to the formation of bond between amino groups of the functionalized carrier and carboxyl groups of carbopol. The combination of amino-functionalization of the carrier with the post-coating of the nanoparticles sustained budesonide release. Further, an in vitro model of inflammatory bowel disease showed that the cytoprotective effect of budesonide loaded in the post-coated silica nanoparticles on damaged HT-29 cells was more pronounced compared to the cytoprotection obtained with pure budesonide
CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL.
Tumor-infiltrating neutrophils have been implicated in malignant development and progression, but mechanisms are ill defined. Neutrophils produce a proliferation-inducing ligand APRIL/TNFSF13, a factor that promotes development of tumors from diverse origins, including diffuse large B-cell lymphoma (DLBCL). High APRIL expression in DLBCL correlates with reduced patient survival, but the pathway(s) dictating APRIL expression are not known. Here, we show that all blood neutrophils constitutively secrete APRIL, and inflammation-associated stimuli, such as TNF, further upregulate APRIL. In a significant fraction of DLBCL patients, tumor cells constitutively produced the ELC-CXC chemokine CXCL-8 (IL8), enabling them to recruit APRIL-producing blood neutrophils. CXCL-8 production in DLBCL was unrelated to the cell of origin, as APRIL-producing neutrophils infiltrated CXCL-8(+) DLBCL from both germinal center (GC) and non-GC subtypes. Rather, CXCL-8 production implied events affecting DNA methylation and acetylation. Overall, our results showed that chemokine-mediated recruitment of neutrophils secreting the tumor-promoting factor APRIL mediates DLBCL progression. Cancer Res; 77(5); 1097-107. ©2016 AACR
Curvature homogeneous spacelike Jordan Osserman pseudo-Riemannian manifolds
Let s be at least 2. We construct Ricci flat pseudo-Riemannian manifolds of
signature (2s,s) which are not locally homogeneous but whose curvature tensors
never the less exhibit a number of important symmetry properties. They are
curvature homogeneous; their curvature tensor is modeled on that of a local
symmetric space. They are spacelike Jordan Osserman with a Jacobi operator
which is nilpotent of order 3; they are not timelike Jordan Osserman. They are
k-spacelike higher order Jordan Osserman for ; they are k-timelike
higher order Jordan Osserman for , and they are not k timelike
higher order Jordan Osserman for .Comment: Update bibliography, fix minor misprint
A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma.
Dysregulated expression of factors that control protein synthesis is associated with poor prognosis of many cancers, but the underlying mechanisms are not well defined. Analysis of the diffuse large B-cell lymphoma (DLBCL) translatome revealed selective upregulation of mRNAs encoding anti-apoptotic and DNA repair proteins. We show that enhanced synthesis of these proteins in DLBCL is mediated by the relief of repression that is normally imposed by structure in the 5'-untranslated regions of their corresponding mRNAs. This process is driven by signaling through mammalian target of rapamycin, resulting in increased synthesis of eukaryotic initiation factor (eIF) 4B complex (eIF4B), a known activator of the RNA helicase eIF4A. Reducing eIF4B expression alone is sufficient to decrease synthesis of proteins associated with enhanced tumor cell survival, namely DAXX, BCL2 and ERCC5. Importantly, eIF4B-driven expression of these key survival proteins is directly correlated with patient outcome, and eIF4B, DAXX and ERCC5 are identified as novel prognostic markers for poor survival in DLBCL. Our work provides new insights into the mechanisms by which the cancer-promoting translational machinery drives lymphomagenesis
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
BACKGROUND: PQR309 is an orally bioavailable, balanced pan-phosphatidylinositol-3-kinase (PI3K), mammalian target of rapamycin (mTOR) C1 and mTORC2 inhibitor. PATIENTS AND METHODS: This is an accelerated titration, 3 + 3 dose-escalation, open-label phase I trial of continuous once-daily (OD) PQR309 administration to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics in patients with advanced solid tumours. Primary objectives were to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). RESULTS: Twenty-eight patients were included in six dosing cohorts and treated at a daily PQR309 dose ranging from 10 to 150 mg. Common adverse events (AEs; ≥30% patients) included fatigue, hyperglycaemia, nausea, diarrhoea, constipation, rash, anorexia and vomiting. Grade (G) 3 or 4 drug-related AEs were seen in 13 (46%) and three (11%) patients, respectively. Dose-limiting toxicity (DLT) was observed in two patients at 100 mg OD (>14-d interruption in PQR309 due to G3 rash, G2 hyperbilirubinaemia, G4 suicide attempt; dose reduction due to G3 fatigue, G2 diarrhoea, G4 transaminitis) and one patient at 80 mg (G3 hyperglycaemia >7 d). PK shows fast absorption (Tmax 1-2 h) and dose proportionality for Cmax and area under the curve. A partial response in a patient with metastatic thymus cancer, 24% disease volume reduction in a patient with sinonasal cancer and stable disease for more than 16 weeks in a patient with clear cell Bartholin's gland cancer were observed. CONCLUSION: The MTD and RP2D of PQR309 is 80 mg of orally OD. PK is dose-proportional. PD shows PI3K pathway phosphoprotein downregulation in paired tumour biopsies. Clinical activity was observed in patients with and without PI3K pathway dysregulation. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov # NCT01940133
- …